Jones RL, Maki RG, Patel SR, et al. - Considering the outcomes of the randomized, phase 3 ET743-SAR-3007 trial, demonstrating trabectedin as efficacious in achieving a significantly longer progression-free survival (PFS) compared with dacarbazine in patients with advanced leiomyosarcoma/liposarcoma after the failure of prior chemotherapy, researchers examined if first infusion site of care influence the safety, efficacy, and patient-reported outcomes related with trabectedin. Trabectedin treatment was provided to 378 patients; 100 (27%) and 277 (73%), respectively, first received trabectedin in the inpatient and outpatient setting. The outcomes of the current study suggested equivalent safety and efficacy in either setting despite receipt of trabectedin as outpatient therapy by the majority of patients.